Skip to main content

Table 3 Crude and adjusted hazard ratios for different outcome events among recruited versus non-recruited women in placebo and non-treatment arms, EPHT Trial, 2001 to 2007

From: Results from a blind and a non-blind randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy (EPHT) Trial

Outcome

Placebo arm

Non-treatment arm

 

Recruited vs non-recruited

Recruited vs non-recruited

 

HR (95% CI), crude

HR (95% CI),

adjusted*

HR (95% CI), crude

HR (95% CI), adjusted*

Coronary heart disease

0.81

(0.62-1.04)

0.80

(0.62-1.03)

1.02

(0.82-1.28)

1.06

(0.84-1.33)

Cancer

1.00

(0.58-1.70)

0.97

(0.57-1.66)

0.71

(0.42-1.20)

0.75

(0.44-1.29)

Cerebrovascular disease

0.43

(0.26-0.71)

0.44

(0.27-0.73)

0.86

(0.59-1.26)

0.90

(0.61-1.31)

Bone fractures

0.89

(0.67-1.18)

0.88

(0.67-1.17)

1.28

(0.97-1.69)

1.30

(0.98-1.72)

Total mortality

0.51

(0.22-1.19)

0.51

(0.23-1.22)

0.72

(0.33-1.55)

0.80

(0.34-1.74)

All outcomes combined

0.76

(0.63-0.91)

0.75

(0.63-0.91)

1.05

(0.89-1.25)

1.09

(0.92-1.30)

  1. *adjusted for age, living-place, education, smoking status, and time since menopause